STAAR Surgical Co stock (US8577001096): Up 2.35% among top monthly gainers

STAAR Surgical Co shares rank among May 2026's top performers with a 2.35% gain, trading at $27.83 amid healthcare sector momentum.

STAAR Surgical Co, a leader in implantable collamer lenses for vision correction, saw its stock rise 2.35% in May 2026, placing it among the best-performing healthcare names for the month with a market cap of $1.39 billion at $27.83 per share, StockTitan as of May 2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: STAAR Surgical Company
• Sector/industry: Healthcare / Medical Devices
• Headquarters/country: United States
• Core markets: Vision correction, ophthalmology
• Key revenue drivers: Implantable Collamer Lenses (ICL)
• Home exchange/listing venue: Nasdaq (STAA)
• Trading currency: USD

STAAR Surgical Co: core business model

STAAR Surgical Co develops and markets minimally invasive ophthalmic products, primarily its proprietary Implantable Collamer Lens (ICL) platform for refractive surgery to correct moderate to high myopia and astigmatism. The ICL is a phakic intraocular lens inserted between the iris and natural lens, offering a reversible alternative to LASIK for patients unsuitable for corneal procedures. This technology targets the growing demand for premium vision correction globally.

Headquartered in the US with manufacturing in Switzerland, STAAR operates through a direct sales force in key markets like the US, Europe, and Asia-Pacific. The company's VISIAN ICL line, including toric and multifocal variants, drives the majority of revenue, supported by surgical accessories and delivery systems. STAAR emphasizes surgeon training and clinical data to expand adoption among ophthalmologists.

Main revenue and product drivers for STAAR Surgical Co

ICL implants account for over 90% of STAAR Surgical Co's net sales, with the VISIAN EVO ICL platform leading growth due to its improved haptic design and central hole for reduced complications. In recent periods, international sales, particularly in China and Japan, have fueled expansion, offsetting slower US uptake where regulatory approvals limit marketing claims. Accessories like injectors contribute steady recurring revenue.

Geographic diversification remains key, with Asia representing a significant portion of ICL volume amid rising disposable incomes and myopia prevalence. STAAR's pipeline includes next-generation ICLs with enhanced materials for broader patient eligibility, positioning it for sustained demand in the $5 billion global refractive surgery market.

Industry trends and competitive position

The ophthalmic devices sector benefits from aging populations and increasing myopia rates, particularly in Asia, driving demand for advanced refractive solutions. STAAR Surgical Co differentiates through its phakic lens expertise, competing with laser-based providers like Johnson & Johnson Vision and Zeiss, but holding a niche in non-corneal procedures. US investors note STAAR's exposure to high-growth emerging markets via Nasdaq listing.

Why STAAR Surgical Co matters for US investors

Listed on Nasdaq as STAA, STAAR Surgical Co offers US investors access to the fast-expanding refractive surgery market, with strong ties to domestic ophthalmology centers and FDA-approved products. Its focus on innovative ICLs aligns with trends in personalized medicine, providing diversification in healthcare portfolios amid broader medtech consolidation.

Conclusion

STAAR Surgical Co continues to leverage its ICL platform amid positive monthly stock performance in May 2026, reflecting healthcare sector tailwinds. With a focus on international growth and product innovation, the company maintains relevance for US investors tracking medtech trends. Market dynamics and competitive pressures warrant ongoing monitoring.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.